SELLAS Life Sciences announced it will present Phase 2 data for SLS009 in relapsed/refractory AML at ASH 2026. The reported data shows promising efficacy, particularly in high-risk subgroups, which could significantly impact investor sentiment and future development plans for the drug.
SELLAS Life Sciences announced that it will present Phase 2 data for its drug SLS009 in relapsed/refractory AML at the ASH 2026 meeting. The disclosed results, including an ORR of 34% overall and higher rates in specific high-risk subgroups (monocytic AML and TP53-mutated AML), are positive, especially given these patients previously failed venetoclax-based therapies. This news is a significant positive catalyst for SELLAS, as it validates the potential of SLS009 and supports its advancement into frontline treatment settings. For traders, this presents a short-term opportunity for upward price movement in SLS stock due to increased investor confidence and long-term potential if the drug continues to show promise in further trials and gains market share in a difficult-to-treat cancer. The key risk is that the full presentation at ASH 2026 might reveal additional details that temper enthusiasm, or future trials may not replicate these results.